RELiZORB for pancreatic insufficiency in tube-fed pancreatitis
Part of Digestive system clinical trials.
This study tests whether the RELiZORB device (which helps digest fat in tube feedings) can improve symptoms for patients with pancreatitis and pancreatic enzyme insufficiency who are in the hospital and rely on a feeding tube for most of their nutrition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe exocrine pancreatic insufficiency (your pancreas does not make enough digestive enzymes).
- You have acute, recurrent acute, or subacute pancreatitis (a recently diagnosed or repeat inflammation of the pancreas with complications).
- You are currently in the hospital for your condition.
- You get at least half of your daily nutrition through a feeding tube (enteral nutrition).
- You are able to understand and agree to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pancreatic enzyme medicine (called NHS7108) for people with exocrine pancreatic insufficiency (EPI). EPI means your pancreas doesn't make enough enzymes to break down food properly. The study aims to see if this new medicine is safe and works well to help your body absorb nutrients.
This trial tests whether enzymes from microbes work as well as enzymes from pigs to help people with chronic pancreatitis digest food better. It aims to find a treatment that reduces symptoms like pain and poor digestion.
This trial tests a new medicine (ANG003) for people with cystic fibrosis who have severe pancreatic problems. It looks at how safe and effective the medicine is, and whether it helps with digestion.
This trial tests whether giving extra IV fluids before, during, and after an ERCP procedure can help prevent a common complication called post-ERCP pancreatitis (inflammation of the pancreas). If you are scheduled for an ERCP, you may be eligible to participate.
This study tests whether a medication called RELiZORB can help adults with moderate to severe acute pancreatitis (sudden, severe pancreas inflammation) tolerate nutrition delivered through a feeding tube. If your body is struggling to accept enough nutrition during acute pancreatitis, this trial may help you receive adequate nutrition while you recover.
This study tests whether RELIZORB helps children with short bowel syndrome (SBS), who rely on IV nutrition (and also tube feeding), absorb fats better. It is an open-label study over 90 days, meaning everyone gets the study treatment and outcomes are compared over time.
Hear when a new Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.